Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting
Corvus will present data on CPI-818 in two poster sessions:
Poster Presentations:
Poster 1571: | Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor that Preferentially Blocks the Growth of T Lymphoma Cells. |
Presenter: | Patrick Ng, PhD, Corvus Senior Scientist |
Poster Session: | 625: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster I |
Date and Time: | Saturday, December 7 from 5:30 pm – 7:30 pm ET |
Location: | Poster Hall / Hall B, Level 2 / Orange County Convention Center |
Poster 4030: | A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2 Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma. |
Presenter: | Mehrdad Mobasher, M.D., Corvus Vice President and Chief Medical Officer |
Poster Session: | 624: Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Poster III |
Date and Time: | Monday, December 9, 2019 from 6:00 pm – 8:00 pm ET |
Location: | Poster Hall / Hall B, Level 2 / Orange County Convention Center |
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus’ lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and blockade of adenosine production. These candidates are being studied in ongoing Phase 1 and 2 clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant, and with pembrolizumab. The Company’s third clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Chief Financial Officer
650-900-4522
LLea@corvuspharma.com
MEDIA CONTACT:
W2O pure
+1 213-262-9390
sseapy@purecommunications.com
Source: Corvus Pharmaceuticals, Inc.